Robert J. Motzer, MD, discusses health-related quality of life (HRQOL) analyses from the phase 3 CLEAR trial of frontline pembrolizumab (Keytruda) plus lenvatinib (Lenvima) in patients with metastatic renal cell carcinoma (RCC). According to Motzer, the results showed that the combination resulted in similar HRQOL outcomes and disease-related symptom scores as single-agent sunitinib (Sutent). Motzer is the Kidney Cancer Section Head, Genitourinary Oncology Service; and Jack and Dorothy Byrne Chair in Clinical Oncology at Memorial Sloan Kettering Cancer Center.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.